Type 2 diabetes and hypercholesterolemia both arise from a combination of genetic predisposition and environmental/lifestyle factors, but treatment practices for these conditions have taken a purely phenotypic approach. Learn how personalised medicine is being applied to treatment decisions in these two conditions, in order to individualise therapy and reduce the risk of cardiovascular morbidity and mortality.


Introduction : Definitions & Objectives of the colloquium: Selective choices among relevant areas with established therapeutic progress. Dominique BELLET et Jean-Paul TILLEMENT

New diagnostic and Therapeutic Technologies

Integration of individual genetic and kinetic characteristics for the pharmacological optimization of drug use. Pierre MARQUET

Toward precision medicine for age-related diseases: standardized geriatric assessmentFati NOURHASHEMI

Genomic and precision medicine: setting problems and perspectives. Francis GALIBERT

Managing drug interactions: a clinical decision support system. Jacques TURGEON

Therapeutic targeting of Interleukin 17: An example of translational medicine. Pierre MIOSSEC

Realities and perspetives of precision medicine

Type 2 diabetes and hypercholesterolemia. André SCHEEN

Should we sequence each patient's tumour?  Christophe LE TOURNEAU

Kidney transplantation: an emblematic example of precision medicine to solve an increasingly complex situation. Thierry HAUET

Gene, cellular and stem-cell therapies: perspectives and limits. Salima HACEIN-BEY

Precision Medicine: which applications, cost and targeted populations? Jean-Pierre MICHEL

Pr Dominique Bellet, Pr Jean-Paul Tillement
André J. Scheen, Liège
Pr Dominique Bellet, Pr Jean-Paul Tillement
André J. Scheen, Liège
The patient
Publication type
Download the publication